Skip Ribbon Commands
Skip to main content
Menu
Clin Asst Prof Mabel Wong

Clin Asst Prof Wong Mabel

MBBS, MRCP (UK), MMed (Singapore), GDFM (Singapore), FAMS

Senior Consultant

National Cancer Centre Singapore

Specialty: Medical Oncology

Sub-specialties: Breast

Conditions Treated by this Doctor:
Breast Cancer.

Clinical Appointments

  • Senior Consultant Division of Medical Oncology National Cancer Centre SingaporeNational Cancer Centre Singapore
  • Visiting Consultant KK Breast Centre KK Women's and Children's HospitalKK Women's and Children's Hospital

Academic Appointments

  • Clinical Asst Professor at Duke-NUS Medical School

Profile

Dr Mabel Wong is a Senior Consultant in the Division of Medical Oncology at National Cancer Centre Singapore, and Visiting Consultant at KKH Breast Surgery Department. She obtained her undergraduate medical degree from the National University of Singapore. Dr. Mabel has been practising in Singapore since 2008, focusing mainly on medical oncology. Her research interests include early phase clinical trials in breast and gynaecology oncology and neo-adjuvant therapy in breast cancer.

She is part of the core faculty for Senior Residency Program (Medical Oncology) in curriculum planning and a clinical tutor at the Yong Loo Lin School of Medicine, Singapore. Her other appointments include being the Chairperson, Chemotherapy Safety Committee at the National Cancer Centre aside from her role as an educator. 

Education

  • 2012 Royal Marsden Hospital (UK) - Fellowship
  • 2011 National University of Singapore - Graduate Diploma in Family Medicine
  • 2011 Academy of Medicine Singapore - FAMS
  • 2007 Royal College of Physicians (UK) - MRCP           
  • 2007 National University of Singapore - MMed
  • 2001 National University of Singapore - MBBS
  • 1995 Raffles Junior College - GCE 'A' levels
  • 1993 Raffles Girls' School - GCE 'O' levels

Professional Appointments and Committee Memberships

  • Royal College of Physicians (Edinburgh)                        Member         2007-current
  • Singapore Society of Oncology (SSO)                            Member         2008-current
  • ESMO (European Society of Medical Oncology)            Member         2009-current
  • ASCO (American Society of Clinical Oncology)              Member         2008-current
  • Fellow of Academy of Medicine                                            

Awards

  • Star Award - Singapore Health Quality Service Awards 2022
  • Outstanding Faculty Award, Residency in SingHealth Excels (RiSE) 2021
  • 2010/2012 Awarded to improve management of chemotherapy induced febrile neutropenia patients in government restructured hospitals -- Ministry of Health Healthcare Quality Innovation and Improvement Grant - Principal Investigator
  • 2009/2010 Singapore Healthcare Quality Service Award - Singapore General Hospital, Singapore
  • 2009/2010 Band 1 Registrar - National Cancer Centre, Singapore
  • 2009 Achieved book prize for best performance in Graduate Diploma of Family Medicine Examination - National University of Singapore
  • 1998 Achieved Dean's List at MBBS Professional Examinations - National University of Singapore Faculty of Medicine
  • 1994 - 1995 Awarded for academic excellence at GCE 'O' levels examinations - Ministry of Education Scholarship

Research Interests

  1. Clinical trials in breast and gynaecology oncology
  2. Neo-adjuvant therapy in breast cancer

Publications

  1. Ding Quan Ng, CJ Tan, BC Soh, ML Tan, SY Loh, YE Tan, HH Ong, PC Teng, JJ Chan, WY Chay, J Lee, G Lai, SY Beh, JY Tan, YS Yap, GE Lee, M Wong, R Dent, Yl Lo, A Chan, WJ Loh. Impact of Cryotherapy on Sensory, Motor and Autonomic Neuropathy in Breast Cancer Patients Receiving Paclitaxel: A Randomized, Controlled Trial. Front Neurol. 2020 Dec 18;11604688.
  2. S Saw, J Lim, SH Lim, M Wong, C Lim, YS Yap. Patterns of relapse after neoadjuvant chemotherapy in breast cancer: implications for surveillance in clinical practice. Breast Cancer Res Treat 2019 Aug; 177(1):197-206.
  3. CJ Tan, SWT Lim, YL Toh, T Ng, A Yeo, M Shwe, KM Foo, P Chu, A Jain, SL Koo, RA Dent, CH Ng, YS Yap, EH Lim, WJ Loh, WY Chay, GE Lee, JY Tan, SY Beh, M Wong, JJ Chan, CC Khor, HK Ho, A Chan. Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy. Mol Neurobiol 2019 Jul; 56(7): 4741-4750.
  4. Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Ng SB, Chua C, Ng M, Gan A, Poon PS, Teo M, Fu C, Leow WQ, Lim KH, Chung A, Koo SL, Choo SP, Ho D, Rozen S, Tan P, Wong M, Burkholder WF, Tan IB. Sci Rep. 2017 Jan 19;7:40737. doi: 10.1038/srep40737. (JIF: 4.847)
  5. A George, R Kristeleit, S Rafii, CO Michie, R Bowen, V Michalarea, T van Hagen, M Wong, G Rallis, LR Molife, J Lopez, U Banerji, SN Banerjee, ME Gore, JS de Bono, SB Kaye, TA Yap. Clinical factors of response in patients with advanced ovarian cancer participating in early phase clinical trials. Eur J Cancer 2017 May; 76:52-59.
  6. LY Lim, H Miao, JSJ Lim, SC Lee, N Bhoo-Pathy, CH Yip, NABM Taib, P Chan, EY Tan, SH Lim, GH Lim, E Woo, YS Tan, JA Lee, M Wong, PH Tan, KW Ong, FY Wong, YS Yap, M Hartman. Outcome after neoadjuvant chemotherapy in Asian breast cancer patients. Cancer Med 2017 Jan; 6(1):173-185. (JIF: 3.362)
  7. Khan KH, Wong M, Rihawi K, Bodla S, Morganstein D, Banerji U, Molife LR. Hyperglycemia and Phosphatidylinositol 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin (PI3K/AKT/mTOR) Inhibitors in Phase 1 Trials: Incidence, Predictive Factors and Management. Oncologist 2016 May 5. pii: theoncologist.2015-0248 [Epub ahead of print] (Joint first author with Khan KH)
  8. Ng T, Teo SM, Yeo HL, Shwe M, Gan YX, Cheung YT, Foo KM, Chan MT, Lee JA, Tan YP, Fam G, Yong WS, Preetha M, Loh WJ, Koo SL, Jain A, Lee GE, Wong M, Dent R, Yap YS, Ng R, Khor CC, Ho HK, Chan A. Brain- derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. Neuro Oncol. 2016 Feb 18;(2):244-251.
  9. Y.T. Cheung, T. Ng, M. Shwe, H.K. Ho, K.M. Foo, M.T. Cham, J.A. Lee, G. Fan, Y.P. Tan, W.S. Yong, P. Madhukumar, S.K. Loo, S.F. Ang, M. Wong, W.Y. Chay, W.S. Ooi, R.A. Dent, Y.S. Yap, R. Ng, A. Chan. Association of pro-inflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: A multi-centered, prospective, cohort study. Annals of Oncology 2015; doi: 10.1093/annonc/mdv206
  10. Xiao-Jun Wang, Mabel Wong, Li-Yang Hsu, Alexandre Chan. Costs Associated with Febrile Neutropenia in Solid Tumor and Lymphoma Patients - An Observational Study in Singapore. BMC Health Serv Res. 2014 Sep 24;14(1):434. doi: 10.1186/1472-6963-14-434.
  11. Chan A, Wong QX, Ali MK, Wong M, Hsu LY. Clinical efficacy of adjunctive G-CSF on solid tumour and lymphoma patients with established febrile neutropenia. Support Care Cancer. 2014 Apr;22(4):1105-12. doi: 10.1007/s00520-013-2067-1. Epub 2013 Dec 7. (JIF: 2.698)
  12. M Wong, S O'Neill, G Walsh, IE Smith. Goserelin with chemotherapy to preserve ovarian function in pre-menopausal women with early breast cancer: menstruation and pregnancy outcomes. Ann Oncol. 2013 Jan; 24(1):133-8. (JIF: 11.855)
  13. Chew SC, Lim J, Singh O, Lee EJD, Wong M, Chowbay B. Genetic variations of NR1I3 and NR2B1 in Asian populations. Drug Metab Pharmacokinet. 2013;28(2):169-76. Epub 2012 Jul 24. (JIF: 2.146)
  14. Wong M, Jara Lazario AR, Ng RCH, Lim AST, Lim TH, Cheok PY, Tan PH, Wong NS. ETV6 Disruption Does Not Predict Indolent Clinical Behavior in Secretory Breast Carcinoma. Breast J. 2012 Nov; 18(6):604-6. (JIF: 2.801)
  15. Wong M, Jin J, Tan MH, Lee YM, Lee TE, Ding Y, Yong HC, Lim SE, Chai LYA, Chau NM, Hsu LY. Prospective Audit of Post-chemotherapy Febrile Neutropenia in Patients with Solid Cancer and Lymphoma in Two Singapore Cancer Centers. Ann Acad Med Singapore. 2012 Jul; 41(7):287-93. (JIF: 0.51)
  16. Lim JS, Chen XA, Singh O, Yap YS, Wong NS, Ng CHR, Wong M, Lee E, Chowbay B. Impact of CYP2D6, CYP3A5, CYP2C9 and CYP2C19 polymorphisms on tamoxifen pharmacokinetics in Asian breast cancer patients. British Journal of Clinical Pharmacology 71(5): 737-750. (JIF: 3.493)
  17. Wong M, Choo SP, Tan EH. Travel Warning with Capecitabine. Ann Oncol 2009 Jul; 20 (7):1281. (JIF: 11.855)

Research Trials